STAT3 is widely recognized as a potential drug target because: a) activation and/or overexpression of STAT3 is widely associated with many human cancers [2–4]; b) it induces tumor-promoting inflammation and suppresses anti-tumor immunity [2]; and c) it induces various anti-apoptotic and/or pro-proliferative gene expressions [2]. Here, STAT3 is linked to cancer.